Third View Private Wealth LLC Acquires Shares of 7,149 Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Third View Private Wealth LLC acquired a new stake of 7,149 shares of Regeneron worth approximately $5.52 million in Q4, representing 0.7% of its portfolio and the firm's 28th-largest holding.
• Several large institutions (Dodge & Cox, AQR, Invesco, Caisse, Man Group) substantially increased their REGN positions, leaving 83.31% of the stock held by institutions, while insiders sold 3,774 shares (~$2.94M) last quarter and now own 7.02%.
• Analyst sentiment is constructive with a consensus "Moderate Buy" and an average price target of $811.96 (including upgrades from Bank of America and raises from Guggenheim), and Regeneron recently beat quarterly EPS and raised its quarterly dividend to $0.94.

Third View Private Wealth LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,149 shares of the biopharmaceutical company's stock, valued at approximately $5,518,000. Regeneron Pharmaceuticals makes up 0.7% of Third View Private Wealth LLC's investment portfolio, making the stock its 28th biggest holding.

A number of other institutional investors and hedge funds have also bought and sold shares of REGN. Dodge & Cox increased its stake in Regeneron Pharmaceuticals by 18.9% during the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company's stock valued at $2,558,804,000 after purchasing an additional 724,562 shares in the last quarter. AQR Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 528.7% during the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company's stock valued at $405,596,000 after purchasing an additional 606,612 shares in the last quarter. Invesco Ltd. increased its stake in Regeneron Pharmaceuticals by 38.0% during the 3rd quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company's stock valued at $834,675,000 after purchasing an additional 408,649 shares in the last quarter. Caisse de depot et placement du Quebec increased its stake in Regeneron Pharmaceuticals by 115.4% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 462,502 shares of the biopharmaceutical company's stock valued at $260,051,000 after purchasing an additional 247,780 shares in the last quarter. Finally, Man Group plc increased its stake in Regeneron Pharmaceuticals by 257.6% during the 3rd quarter. Man Group plc now owns 271,707 shares of the biopharmaceutical company's stock valued at $152,773,000 after purchasing an additional 195,724 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, SVP Jason Pitofsky sold 2,036 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,774 shares of company stock worth $2,942,738 in the last quarter. Company insiders own 7.02% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on REGN shares. Bank of America raised shares of Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and boosted their price objective for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an "outperform" rating for the company in a report on Wednesday, April 8th. Piper Sandler started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an "overweight" rating and a $875.00 price objective for the company. Barclays started coverage on shares of Regeneron Pharmaceuticals in a report on Friday, March 6th. They set an "overweight" rating and a $923.00 price objective for the company. Finally, Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a "buy" rating in a report on Monday, February 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $811.96.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: EU approval expands Dupixent pediatric label to ages 2–11 for chronic spontaneous urticaria (CSU), making Dupixent the first targeted option in the region for this age group; this broadens the drug’s addressable market and supports continued sales growth for Regeneron (co-developer with Sanofi). SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
• Positive Sentiment: Regeneron struck a strategic radiopharmaceutical alliance with Telix to co-develop and co-commercialize next‑generation radiopharma oncology therapies on a 50/50 cost/profit basis; Telix gets $40M upfront for four initial programs with large upside potential (reported deal totals in the multi‑billion range). This accelerates Regeneron’s entry into precision oncology with lower upfront capital and shared commercial risk—positive for long‑term pipeline diversification and value creation. Regeneron and Telix Announce Strategic Radiopharma Collaboration
• Positive Sentiment: An analyst price target was raised to $796, signaling increased analyst confidence in Regeneron’s outlook and providing a potential near‑term sentiment lift if other analysts follow. Regeneron Pharmaceuticals NASDAQ: REGN Price Target Raised to $796.00
• Positive Sentiment: Public endorsements continue: Jim Cramer commented favorably on Regeneron’s leadership and momentum, which can boost retail investor interest and trading flows. Jim Cramer on Regeneron (REGN): “I Think The Stock’s Breaking Out Here”
• Neutral Sentiment: Coverage/industry pieces highlight investor tools and market timing (e.g., Zacks commentary about using Earnings ESP); these are broader market signals rather than company‑specific catalysts. Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $746.46 on Tuesday. The firm's 50 day moving average price is $767.25 and its 200-day moving average price is $722.41. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $78.92 billion, a PE ratio of 17.96, a price-to-earnings-growth ratio of 1.99 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the prior year, the business earned $12.07 EPS. The business's quarterly revenue was up 2.5% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.